BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 8494545)

  • 1. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.
    Bouffard DY; Laliberté J; Momparler RL
    Biochem Pharmacol; 1993 May; 45(9):1857-61. PubMed ID: 8494545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
    Baker JA; Wickremsinhe ER; Li CH; Oluyedun OA; Dantzig AH; Hall SD; Qian YW; Ring BJ; Wrighton SA; Guo Y
    Drug Metab Dispos; 2013 Mar; 41(3):541-5. PubMed ID: 23230131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
    van Haperen VW; Veerman G; Vermorken JB; Pinedo HM; Peters G
    Biochem Pharmacol; 1996 Apr; 51(7):911-8. PubMed ID: 8651941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene.
    Beauséjour CM; Gagnon J; Primeau M; Momparler RL
    Biochem Biophys Res Commun; 2002 May; 293(5):1478-84. PubMed ID: 12054682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells.
    Eliopoulos N; Cournoyer D; Momparler RL
    Cancer Chemother Pharmacol; 1998; 42(5):373-8. PubMed ID: 9771951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2',2'-difluorodeoxycytidine.
    Xu YZ; Plunkett W
    Biochem Pharmacol; 1992 Nov; 44(9):1819-27. PubMed ID: 1449536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.
    Heinemann V; Xu YZ; Chubb S; Sen A; Hertel LW; Grindey GB; Plunkett W
    Cancer Res; 1992 Feb; 52(3):533-9. PubMed ID: 1732039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.
    Laliberté J; Marquez VE; Momparler RL
    Cancer Chemother Pharmacol; 1992; 30(1):7-11. PubMed ID: 1375134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleotide specificity of human deoxycytidine kinase.
    Shewach DS; Reynolds KK; Hertel L
    Mol Pharmacol; 1992 Sep; 42(3):518-24. PubMed ID: 1406603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
    Hodge LS; Taub ME; Tracy TS
    Drug Metab Dispos; 2011 Nov; 39(11):2013-6. PubMed ID: 21832002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
    Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
    Kroep JR; Loves WJ; van der Wilt CL; Alvarez E; Talianidis I; Boven E; Braakhuis BJ; van Groeningen CJ; Pinedo HM; Peters GJ
    Mol Cancer Ther; 2002 Apr; 1(6):371-6. PubMed ID: 12477049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclopentenyl cytosine-induced activation of deoxycytidine kinase increases gemcitabine anabolism and cytotoxicity in neuroblastoma.
    Bierau J; van Gennip AH; Leen R; Meinsma R; Caron HN; van Kuilenburg AB
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):105-13. PubMed ID: 16133534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
    Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
    Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
    Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.
    Ohmine K; Kawaguchi K; Ohtsuki S; Motoi F; Egawa S; Unno M; Terasaki T
    Pharm Res; 2012 Jul; 29(7):2006-16. PubMed ID: 22419259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine.
    Vande Voorde J; Sabuncuoğlu S; Noppen S; Hofer A; Ranjbarian F; Fieuws S; Balzarini J; Liekens S
    J Biol Chem; 2014 May; 289(19):13054-65. PubMed ID: 24668817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylation of deoxycytidine kinase on Ser-74: impact on kinetic properties and nucleoside analog activation in cancer cells.
    Amsailale R; Van Den Neste E; Arts A; Starczewska E; Bontemps F; Smal C
    Biochem Pharmacol; 2012 Jul; 84(1):43-51. PubMed ID: 22490700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
    Shord SS; Patel SR
    J Exp Clin Cancer Res; 2009 Jun; 28(1):76. PubMed ID: 19500405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
    Kroep JR; van Moorsel CJ; Veerman G; Voorn DA; Schultz RM; Worzalla JF; Tanzer LR; Merriman RL; Pinedo HM; Peters GJ
    Adv Exp Med Biol; 1998; 431():657-60. PubMed ID: 9598147
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.